acy results have been limited to small-scale clinical studies in which the safety profiles have not been well-identified. The safety profiles will be critical for COVID-19 patients with underlying comorbidities such as cardiovascular dysfunction. Therefore, as there is a need for rapid clinical translation and a wide use of novel therapies fo